PGNX – Progenics Pharmaceuticals Upcoming catalysts

When:
July 30, 2018 @ 7:07 pm – 8:07 pm
2018-07-30T19:07:00-04:00
2018-07-30T20:07:00-04:00

PGNX – Progenics Pharmaceuticals has an upcoming PDUFA priority review for Azedra, and Phase3 Top-line results for z1404, a PSMA-targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer which are expected in the third quarter of 2018.

AZEDRA, Ultra-Orphan Radiotherapeutic Candidate
AZEDRA New Drug Application (NDA) FDA Action Date Set for July 30th
In March 2018, Progenics announced a three-month extension of the review period for the NDA for AZEDRA in patients with malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma, rare neuroendocrine tumors for which there are currently no approved treatment options in the U.S. AZEDRA holds Breakthrough Therapy designation, Orphan Drug status, as well as Fast Track designation.

I think PGNX could move into the PDUFA review, but I am concerned there is no insider buying, and it had a presentation at the Jefferies 2018 Healthcare Conference in New York City, after which the stock started to go down in value ($9 to $8). I would like a stable chart, and start to get bullish before entering. I would like to enter below $8.40 for a ride to over $11 where I would take profits. Stop $8.

PGNX appears to have enough cash on hand not to do an offering (according to finviz), $1.15/ share with 72M share float.

SEC Filings for PGNX: http://ir.progenics.com/financial-information/sec-filings